Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Journavx received FDA approval, the agency announced on Thursday, Jan. 30. The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system, ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

Health and Human Services Secretary Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Look for Journavx to become a massive blockbuster drug for Vertex. It won U.S. Food and Drug Administration (FDA) approval earlier this year for treating acute pain. The big plus for Journavx is ...

So JOURNAVX is a NaV1.8 inhibitor, it is a medicine that targets this particular channel that has been called the holy grail of pain drug development, NAV 1.7 and NaV 1.8. We have programs in both ...

Innovative new drug approvals continued despite worries about FDA constraints. The FDA approved Vertex Pharmaceuticals’ Journavx, the first non-opioid painkiller in more than 20 years.

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...